C4 Therapeutics, Inc.
CCCC
$2.61
-$0.08-2.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 112.79% | -26.90% | -46.17% | 138.17% | 58.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 112.79% | -26.90% | -46.17% | 138.17% | 58.75% |
| Cost of Revenue | -7.16% | -18.37% | 10.29% | 20.14% | -315.80% |
| Gross Profit | 14.89% | 10.42% | -67.99% | -1.74% | 360.83% |
| SG&A Expenses | -11.51% | -24.20% | -9.57% | -9.31% | 0.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.34% | -19.94% | 4.53% | 10.91% | 5.40% |
| Operating Income | 38.62% | 16.16% | -32.92% | 2.08% | -0.75% |
| Income Before Tax | 40.87% | -30.41% | -46.87% | 7.19% | 0.10% |
| Income Tax Expenses | -7.63% | -- | -- | -- | -52.71% |
| Earnings from Continuing Operations | 40.75% | -30.41% | -46.87% | 7.19% | 0.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.75% | -30.41% | -46.87% | 7.19% | 0.52% |
| EBIT | 38.62% | 16.16% | -32.92% | 2.08% | -0.75% |
| EBITDA | 38.98% | 16.48% | -32.83% | 2.13% | -0.63% |
| EPS Basic | 64.18% | -25.12% | -42.29% | 10.33% | 27.78% |
| Normalized Basic EPS | 63.87% | 16.62% | -28.53% | 1.90% | 27.26% |
| EPS Diluted | 64.18% | -25.12% | -42.29% | 10.33% | 27.78% |
| Normalized Diluted EPS | 63.87% | 16.62% | -28.53% | 1.90% | 27.26% |
| Average Basic Shares Outstanding | 65.40% | 4.22% | 3.19% | 3.51% | 37.76% |
| Average Diluted Shares Outstanding | 65.40% | 4.22% | 3.19% | 3.51% | 37.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |